Nonclinical cardiovascular safety evaluation of romosozumab, an inhibitor of sclerostin for the treatment of osteoporosis in postmenopausal women at high risk of fracture

Publication date: Available online 23 June 2020Source: Regulatory Toxicology and PharmacologyAuthor(s): James R. Turk, Aimee M. Deaton, Jun Yin, Marina Stolina, Melanie Felx, Gabrielle Boyd, Jean-Guy Bienvenu, Aurore Varela, Martin Guillot, Gill Holdsworth, Alison Wolfreys, Denise Dwyer, Sheetal V. Kumar, Emily M. de Koning, Yusheng Qu, Michael Engwall, Kathrin Locher, Lucas D. Ward, Charles Glaus, Yudong D. He
Source: Regulatory Toxicology and Pharmacology - Category: Toxicology Source Type: research